• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 17, 2019 at 09:52: PM
via Since unveiling its Tecentriq monotherapy win in previously untreated non-small lung cancer, Roche has faced criticism that the diagnostic test it used to identify trial patients might have influenced its results. Not so, says a new analysis presented at the ESMO Immuno-Oncology Congress.

article source
 




Top Bottom
Back
Quote